Cynomolgus IL-6, His Tag (IL6-C5249) is expressed from human 293 cells (HEK293). It contains AA Ala 28 - Met 212 (Accession # P79341-1).
Predicted N-terminus: His
Request for sequence
This protein carries a polyhistidine tag at the N-terminus.
The protein has a calculated MW of 22.9 kDa. The protein migrates as 26-30 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Less than 1.0 EU per μg by the LAL method.
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
Cynomolgus IL-6, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
The purity of Cynomolgus IL-6, His Tag (Cat. No. IL6-C5249) is more than 90% and the molecular weight of this protein is around 25-38 kDa verified by SEC-MALS.
Immobilized Cynomolgus IL-6, His Tag (Cat. No. IL6-C5249) at 5 μg/mL (100 μL/well) can bind Biotinylated Human IL-6 R alpha, Fc,Avitag (Cat. No. ILR-H82F9) with a linear range of 0.6-39 ng/mL (QC tested).
Interleukin 6 (IL-6) is also known as HGF, BSF2,HSF, IFNB2 and IL-6, originally identified as a B cell differentiation factor, is a multifunctional cytokine that regulates immune responses, hematopoiesis, acute phase responses, and inflammatory reactions.It is secreted by T cells, macrophages , monocytes, fibroblasts,endothelial cells,et.al. to stimulate immune response to trauma, especially burns or other tissue damage leading to inflammation. Interleukin 6 has been shown to interact with interleukin-6 receptor and glycoprotein. IL-6 is relevant to many disease processes such as diabetes,atherosclerosis, depression,Alzheimer's Disease,systemic,lupus erythematosus,prostate cancer and rheumatoid arthritis. Advanced/metastatic cancer patients have higher levels of IL-6 in their blood.Hence there is an interest in developing anti-IL-6 agents as therapy against many of these diseases.